Arvinas Directors Dump Zero‑Cost Stock Grants, Backing Their Protein‑Degradation Gamble【Flash】
Arvinas insider buys signal confidence in its protein‑degradation oncology platform—investors eye upcoming earnings for growth cues.
4 minutes to read
ARVINAS INC
Arvinas CFO’s Routine Tax Sale Signals Steady Insider Confidence Amid Leadership Shake‑ups
Arvinas CFO’s routine tax‑sale of 5,696 shares shows disciplined insider liquidity management amid leadership changes, underscoring steady confidence in the biotech’s long‑term prospects.
3 minutes to read
Arvinas’ CSO’s Routine June Sale Mirrors Tax‑Withholding Norm Amid Big Licensing Deal
Arvinas insider trading update: CSO Angela Cacace sells 2,576 shares amid a $70M VEPPANU™ licensing deal—routine tax‑withholding, no signal of market shift.
3 minutes to read
CFO Saik Andrew’s Tax‑Driven Sale Amid Arvinas’ Big Rigel‑Pfizer Deal Raises Insider‑Selling Questions
Arvinas CFO’s tax‑driven sale of 11,139 shares amid a high‑profile licensing deal shows insiders stay bullish, not a confidence drop – read the full insider‑trade analysis.
3 minutes to read
Arvinas Insider Trading: CMO Noah Berkowitz’s Routine RSU Sale Leaves Executive Buying Surge Unchanged
Arvinas insider activity shows routine RSU tax sales by Chief Medical Officer Noah Berkowitz, while top execs boost confidence with bulk buying amid promising Parkinson’s trial data.
3 minutes to read
Arvinas CFO and CEO Sell Thousands of Shares in Routine RSU Tax Sale, Stock Holds Steady Momentum
Arvinas insider sales are routine, not a red‑flag. Loomis’s tax‑sale shows standard RSU settlement; the company’s biotech pipeline remains a key focus.
3 minutes to read